Abstract:Background and objective: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC) is the most prevalent subtype of all BCs. The primary treatment modality is endocrine therapy (ET). Traditional adjuvant ET for early-stage breast cancer (EBC) has undergone extensive exploration and is relatively well-established. However, patients at high risk of recurrence may still experience early relapse, necessitating consideration of intensified adjuvant ET to reduce recurrence risk. The objective of this narrative review is to examine various strategies for intensifying adjuvant ET in EBC, thoroughly analyze key clinical studies, and summarize the most effective treatment approaches supported by current evidence-based medicine. Furthermore, it addresses unresolved challenges that necessitate further refinement and investigation. Methods: As of March 2024, a comprehensive literature search, compilation, and analysis were conducted across PubMed, Baidu Scholar, ClinicalTrials.gov, and relevant academic conferences. Key content and findings: There are numerous methods to intensify adjuvant ET: (I) combining ovarian function suppression (OFS) to reduce estrogen levels in the body and induce a state of artificial menopause to enhance the efficacy of ET; (II) individual extension of the duration of ET based on patients' varying risks of recurrence, with high-risk patients covering two peak recurrence periods; (III) the addition of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) can significantly extend invasive disease-free survival and reduce the risk of recurrence, serving as the main intensive treatment for high-risk patients; (IV) combination with bone-modifying drugs (BMD) can significantly reduce rates of bone metastasis and slightly enhance prognosis but is not commonly used in adjuvant settings; (V) combined with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, current studies only show a trend towards benefit in HR+ patients with germline BRCA1/2 mutations; more data are still needed to support its clinical benefit. This narrative review examines various strategies for intensifying adjuvant ET in EBC, critically evaluates key clinical studies, and summarizes the most effective treatment approaches supported by current evidence-based medicine. Furthermore, it addresses unresolved challenges that necessitate further refinement and investigation. Conclusions: In the context where traditional adjuvant ET is relatively well-established, the emergence of novel ET has notably addressed issues of endocrine resistance more effectively. Various intensified adjuvant ET has shown potential in further reducing recurrence risk among high-risk patients. However, additional research and time are essential to determine the optimal approaches for intensified adjuvant ET.

Extended Endocrine Therapy of Breast Cancer

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

[Efficacy of Adjuvant Endocrine Therapy in Breast Cancer Patients with a Positive-to-negative Switch of Hormone Receptor Status after Neoadjuvant Chemotherapy].

A narrative review: research progress of adjuvant intensive endocrine therapy for early breast cancer

Identify High Risk Estrogen Receptor-Positive Breast Cancer Patients for Extended Endocrine Therapy.

Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy

Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.

ER-positive Breast Cancer Patients with More Than Three Positive Nodes or Grade 3 Tumors Are at High Risk of Late Recurrence after 5-Year Adjuvant Endocrine Therapy

Adjuvant treatment strategy evolution and risk stratification for hormone receptor-positive, human epidermal growth factor receptor-2 negative early breast cancer in China

Case Report: Prolonged Clinical Benefit of ESG401, a Novel Trophoblast Cell-Surface Antigen 2 (Trop-2) Antibody-Drug Conjugate (ADC), in a Patient with Endocrine- Refractory Hormone Receptor-Positive, HER-2 Negative Metastatic Breast Cancer

Impact of Clinicopathological Factors on Extended Endocrine Therapy Decision Making in Estrogen Receptor–positive Breast Cancer

Impact of Adjuvant Chemotherapy on the Survival of Patients with Estrogen Receptor ≥50 ％, Human Epidermal Growth Factor Receptor-2 Negative, Lymph Node Negative Breast Cancer

Clinical Outcomes with First-Line Chemotherapy Versus Endocrine Therapy for Adjuvant Endocrine Therapy-Resistant Metastatic Breast Cancer

Preventing late recurrence in hormone receptor-positive early breast cancer: a review

Research Progress on Predictive Factors for Endocrine Therapy in Breast Cancer

162P Overcoming Resistance to Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Meta-Analysis of Randomized Clinical Trials

Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis

The role of adjuvant endocrine treatment in ER+, PR−, HER2− early breast cancer: a retrospective study of real-world data

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China